Immunomedics (NASDAQ:IMMU) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a report issued on Monday.

Several other equities analysts also recently commented on the company. Zacks Investment Research downgraded Immunomedics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 15th. Jefferies Group upped their target price on Immunomedics from $14.00 to $16.00 and gave the company a “buy” rating in a research report on Monday, October 9th. Finally, BidaskClub raised Immunomedics from a “hold” rating to a “buy” rating in a research report on Wednesday, August 23rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $15.33.

Immunomedics (IMMU) opened at $9.03 on Monday. Immunomedics has a 12-month low of $3.30 and a 12-month high of $14.48. The company has a current ratio of 0.74, a quick ratio of 0.74 and a debt-to-equity ratio of -0.29.

In related news, Director Brian A. Markison sold 8,390 shares of the business’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $11.89, for a total value of $99,757.10. Following the completion of the sale, the director now directly owns 99,178 shares in the company, valued at $1,179,226.42. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Behzad Aghazadeh purchased 1,325,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The stock was bought at an average price of $10.47 per share, with a total value of $13,872,750.00. The disclosure for this purchase can be found here. Insiders own 6.60% of the company’s stock.

Hedge funds have recently modified their holdings of the stock. Amalgamated Bank boosted its stake in shares of Immunomedics by 8.1% in the second quarter. Amalgamated Bank now owns 12,911 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 966 shares during the period. Stephens Inc. AR bought a new stake in Immunomedics during the second quarter worth $115,000. Raymond James Financial Services Advisors Inc. lifted its stake in Immunomedics by 11.4% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 14,400 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 1,473 shares during the last quarter. SG Americas Securities LLC lifted its stake in Immunomedics by 99.3% during the second quarter. SG Americas Securities LLC now owns 20,719 shares of the biopharmaceutical company’s stock worth $183,000 after purchasing an additional 10,323 shares during the last quarter. Finally, Legal & General Group Plc lifted its stake in Immunomedics by 7.4% during the second quarter. Legal & General Group Plc now owns 25,477 shares of the biopharmaceutical company’s stock worth $222,000 after purchasing an additional 1,747 shares during the last quarter. Institutional investors and hedge funds own 76.32% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://theolympiareport.com/2017/12/06/valuengine-downgrades-immunomedics-immu-to-sell.html.

Immunomedics Company Profile

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Receive News & Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.